logo BDSP

Base documentaire


  1. The cost-effectiveness of strategies to assess gastroesophageal reflux as an exacerbating factor in asthma.

    Article - En anglais

    OBJECTIVES 

    We sought to evaluate the cost-effectiveness of diagnostic strategies to determine whether or not acid reflux exacerbates asthma, and to identify which asthma response probabilities are most important in a cost-effective workup of this problem.

    METHODS 

    We performed a cost-effectiveness analysis, comparing 11 diagnostic strategies to assess the role that acid reflux plays in asthma.

    Probabilities and costs were derived from the published literature.

    Average and incremental costs, effectiveness, and cost-effectiveness were calculated for each strategy.

    Sensitivity analyses were performed.

    RESULTS 

    The most cost-effective diagnostic approach is to begin with omeprazole 20 mg/day for 3 months, followed by 24-h pH testing on drug in nonresponders.

    If 24-h pH testing is positive, increase the omeprazole dose every 3 months until the patient responds or a maximum of 60 mg/day is given.

    This strategy costs $730 per case correctly diagnosed.

    When the cost of pH testing exceeds $586 or the cost of omeprazole 20 mg/day is<$53 per month, omeprazole 20 mg/day for 3 months followed by 60 mg/day for the same duration in nonresponders becomes more cost-effective.

    CONCLUSIONS 

    Empiric acid reflux suppression, followed by pH testing in nonresponders, is the most cost-effective means of determining whether GERD is aggravating a pa-tient's asthma.

    Mots-clés Pascal : Reflux gastrooesophagien, Complication, Aggravation, Asthme, Diagnostic, Coût, Sensibilité, Analyse avantage coût, Homme, Appareil digestif pathologie, Oesophage pathologie, Appareil respiratoire pathologie, Bronchopneumopathie obstructive, Economie santé, Test therapeutique

    Mots-clés Pascal anglais : Gastroesophageal reflux, Complication, Aggravation, Asthma, Diagnosis, Costs, Sensitivity, Cost benefit analysis, Human, Digestive diseases, Esophageal disease, Respiratory disease, Obstructive pulmonary disease, Health economy, Tgerapy-based diagnosis

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0321987

    Code Inist : 002B24J. Création : 16/11/1999.